Canton Strategic Holdings (CNTN) Non Operating Income (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Non Operating Income of -$14.7 million for Q1 2026, up 33.17% on a QoQ basis from -$22.0 million in Q4 2025, and down 296074.34% year-over-year from N/an in Q1 2025.
Canton Strategic Holdings (CNTN) Non Operating Income (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Non Operating Income history runs 6 years deep, the most recent figure standing at -$14.7 million for Q1 2026.
- Quarterly Non Operating Income fell 296074.34% year-over-year to -$14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.7 million (down 24565.74% YoY) and the FY2025 annual result came in at -$22.0 million, down 9412.05% from the prior year.
- Non Operating Income was -$14.7 million for Q1 2026 at Canton Strategic Holdings, up from -$22.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $91194.0 in Q1 2024 and bottomed at -$22.0 million in Q4 2025.
- A 5-year average of -$2.7 million and a median of $25532.5 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 249.27% — and 2026, when it tumbled 296074.34%.
- Canton Strategic Holdings' Non Operating Income stood at -$1.6 million in 2022, then soared by 103.61% to $57379.0 in 2023, then tumbled by 53.09% to $26914.0 in 2024, then sank by 81804.72% to -$22.0 million in 2025, then soared by 33.17% to -$14.7 million in 2026.
- Business Quant data shows CNTN's Non Operating Income at -$14.7 million in Q1 2026, -$22.0 million in Q4 2025, and -$8260.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | -14.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.70 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | -8,260.00 |
| Jun 30, 2025 | -3,993.00 |
| Mar 31, 2025 | 4,965.00 |
| Dec 31, 2024 | 26,914.00 |
| Sep 30, 2024 | 69,719.00 |
| Jun 30, 2024 | 48,397.00 |
| Mar 31, 2024 | 91,194.00 |
| Dec 31, 2023 | 57,379.00 |
| Sep 30, 2023 | 24,955.00 |
| Jun 30, 2023 | 27,682.00 |
| Mar 31, 2023 | 26,110.00 |
| Mar 31, 2022 | -1.59 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | -312,323.00 |
| Jun 30, 2021 | -458,371.00 |
| Mar 31, 2021 | -782,463.00 |